Can Steroids Shrink Tumors? Their Role in Cancer Treatment

Steroids can directly kill certain cancer cells, but only in a narrow category of malignancies. In blood cancers that arise from lymphoid cells, glucocorticoids like dexamethasone and prednisone trigger those cancer cells to self-destruct, making them a genuine tumor-shrinking treatment. For the majority of solid tumors, though, steroids do not attack the cancer itself. Their role in cancer care is still enormous, spanning everything from controlling brain swelling around tumors to preventing chemotherapy-induced nausea, but the mechanism is supportive rather than directly anti-tumor. The distinction matters because how steroids help depends entirely on what kind of cancer is being treated and what problem the oncologist is trying to solve.

Where Steroids Actually Kill Cancer Cells

Glucocorticoids have a well-established ability to destroy lymphoid cells, a property oncologists call “lympholytic.” This makes them a cornerstone of treatment for several blood cancers, most prominently acute lymphoblastic leukemia (ALL), certain lymphomas, and multiple myeloma. In ALL, for instance, glucocorticoids are included in virtually every standard chemotherapy regimen because they induce apoptosis in the malignant lymphoblasts, effectively commanding those cells to die. A good early response to steroids in ALL is actually one of the strongest predictors of long-term survival.

The catch is that this direct killing effect is essentially limited to cancers of the lymphoid lineage. Preclinical and some clinical data suggest that in solid tumors, glucocorticoids may actually work against treatment by inducing a state of cell-cycle arrest that protects tumor cells from chemotherapy and radiation rather than sensitizing them to it.¹ That is a troubling reversal: the same drug that kills one type of cancer cell may shield another type from the drugs meant to destroy it. This is why oncologists think carefully about which patients receive steroids as part of their anti-cancer regimen versus which patients receive them purely for symptom control.

Why Brain Tumors Seem to Shrink on Steroids

One of the most dramatic visible effects of steroids in oncology happens in the brain. When a tumor grows inside the skull, it often causes the surrounding blood vessels to become abnormally leaky, allowing fluid to accumulate in the tissue around the tumor. This peritumoral edema can cause severe neurological symptoms, from headaches and confusion to weakness and seizures. Dexamethasone, the steroid most commonly used in this setting, can reduce this swelling within hours. On a follow-up brain scan, the mass may appear to have shrunk, but what actually changed is the fluid buildup around it, not the tumor itself.

Research into the mechanism shows that dexamethasone works through at least two pathways: it reduces the production of vascular permeability factor (now usually called VEGF) by the tumor cells themselves, and it also makes the surrounding blood vessels less responsive to the permeability signals the tumor sends out.² The result is a rapid decrease in the leakiness that causes edema. For patients with life-threatening brain swelling, this can be lifesaving, buying time for surgery, radiation, or chemotherapy to target the tumor directly. But it is important to understand that the tumor mass is still there; the steroid addressed the swelling, not the underlying malignancy.

Emergency Use in Spinal Cord Compression

A similar logic applies when cancer spreads to the spine. Metastatic spinal cord compression is an oncologic emergency: tumor deposits pressing on the spinal cord can cause paralysis if not treated rapidly. High-dose dexamethasone is typically started as soon as the diagnosis is made, followed by a tapering course of oral steroids.³ The goal is to reduce inflammation and edema around the compressed cord, preserving neurological function while definitive treatment (usually surgery or radiation) is arranged.

Data from a large European study of patients with metastatic spine disease found that most patients received steroids for one to seven days before surgery. Of those treated, about half continued to deteriorate neurologically despite steroids, while roughly 30% stabilized and 20% actually improved before surgery. Among those who did stabilize or improve, the benefit lasted more than 48 hours in about half.⁴ Steroids are not a cure here. They are a bridge, holding the line while the surgical or radiation team takes over.

Steroids as Chemotherapy Partners

Even when steroids do not touch the cancer directly, they play a critical support role during chemotherapy. Nausea and vomiting from chemotherapy can be severe enough to make patients refuse further treatment, and dexamethasone is considered a first-line drug for preventing chemotherapy-induced nausea and vomiting.⁵ For lower-risk chemotherapy regimens, dexamethasone alone may be sufficient. For more intensely nauseating regimens, it is combined with other anti-nausea drugs, and the combination is more effective than either drug class alone.⁶

Steroids also reduce allergic reactions to certain chemotherapy drugs, decrease tissue inflammation that chemotherapy can provoke, and help maintain appetite and energy during treatment. These benefits are not trivial. A patient who can eat, sleep, and tolerate the full course of their chemotherapy has a meaningfully better chance of a good outcome than one who drops doses or stops treatment because of unbearable side effects.

The Immunotherapy Complication

Here is where steroids become genuinely controversial in modern oncology. Immune checkpoint inhibitors, the immunotherapy drugs that have transformed treatment for lung cancer, melanoma, kidney cancer, and many other tumors, work by unleashing the patient’s own immune system against the cancer. Steroids, by their nature, suppress the immune system. That creates an obvious tension, and the data bear it out.

In two independent groups of patients with non-small cell lung cancer receiving checkpoint inhibitors, those who were on steroids at the start of immunotherapy had dramatically worse outcomes. In one cohort, patients not taking steroids had a median overall survival of 21 months compared with about 8 months for those on steroids. In the second cohort, the gap was similarly stark: roughly 16 months versus under 4 months.⁷ Steroid use was the single strongest independent risk factor for disease progression and death in both cohorts. A multi-tumor study confirmed that the response rate to immunotherapy dropped significantly in patients who were exposed to steroids within 30 days before starting treatment, and even patients on the lowest doses fared worse than those who took no steroids at all.⁸

This creates a difficult clinical problem. Sometimes patients need steroids before starting immunotherapy because of brain edema, pain, or other urgent symptoms. Oncologists have to weigh the immediate benefit of symptom control against the possibility that those same steroids are dampening the very immune response the immunotherapy depends on. Timing and dose both matter: the negative effect appears strongest when steroids are given right around the start of immunotherapy and increases with higher cumulative doses. When possible, oncologists try to taper patients off steroids before beginning checkpoint inhibitors.

When Steroids Manage Immunotherapy’s Own Side Effects

Adding to the complexity, steroids are also the primary treatment for the immune-related side effects that checkpoint inhibitors themselves cause. Immunotherapy can provoke the immune system to attack healthy organs, causing inflammation of the colon, liver, lungs, skin, thyroid, and other tissues. These immune-related adverse events range from mild rashes to life-threatening organ damage. Guidelines recommend high-dose corticosteroids for more severe reactions.⁹

This puts oncologists in a bind: the patient needs steroids to survive the side effect, but those steroids may undermine the treatment that caused it. Analysis from clinical trials found that the vast majority of patients who developed these side effects received corticosteroids, and about one in ten needed additional immunosuppressive drugs beyond steroids.¹⁰ Whether these treatment-necessary steroids carry the same immunotherapy-blunting risk as “baseline” steroids given for other reasons is an active research question and one of the most important unanswered questions in immunotherapy right now.

The Prostate Cancer Exception

In prostate cancer, steroids serve yet another distinct purpose. Abiraterone acetate, a widely used drug for advanced prostate cancer, blocks an enzyme involved in androgen production to starve the cancer of the hormones it needs to grow. But that same enzyme is also involved in making cortisol, the body’s natural steroid hormone. Blocking it causes cortisol levels to drop, which triggers a compensatory hormonal cascade that can lead to fluid retention, high blood pressure, and dangerously low potassium levels.¹¹

Low-dose prednisone (typically 5 mg twice daily) is given alongside abiraterone specifically to replace the missing cortisol and shut down that compensatory surge.¹² The steroid here is not fighting the cancer or managing symptoms of chemotherapy. It is correcting a hormonal imbalance created by the cancer drug itself. Without it, the side effects of abiraterone would be much harder to manage, and some patients would have to stop a treatment that is keeping their cancer in check.

Steroid Resistance in Blood Cancers

Even in the blood cancers where steroids genuinely kill tumor cells, resistance is a major clinical problem. Many patients with acute lymphoblastic leukemia respond well to glucocorticoids during the initial phase of treatment, but prolonged exposure can lead to steroid resistance, where the leukemia cells stop dying in response to the drug.¹³ This is one of the most significant obstacles in treating relapsed leukemia.

Researchers have traced part of this resistance to mutations in the gene for the glucocorticoid receptor itself, called NR3C1. In pediatric T-cell ALL, inactivating mutations or deletions of NR3C1 have been found in roughly 7% of patients at diagnosis, meaning some leukemias arrive already resistant to steroids before any treatment begins.¹⁴ Additional studies have identified specific mutations in the NR3C1 gene that cause the receptor to lose function, confirming that these genetic changes play a direct role in treatment failure and relapse.¹⁵ Understanding these resistance pathways is important because it opens the door to testing for resistance early and adapting treatment before the standard steroid regimen fails.

Steroids in Palliative and Supportive Care

For patients with advanced cancer that is no longer curable, steroids address some of the most debilitating symptoms. Cancer-related fatigue, loss of appetite, and the wasting syndrome known as cachexia profoundly affect quality of life. A randomized, placebo-controlled trial found that methylprednisolone produced meaningful improvements in fatigue, appetite, and patient satisfaction compared with placebo in patients with advanced cancer who were already on opioids for pain.¹⁶

A systematic review and meta-analysis pooling data from multiple trials confirmed that systemic corticosteroids modestly reduce cancer-related fatigue and appetite loss while improving overall quality of life, without a significant increase in serious adverse events in the short term.¹⁷ The benefit, however, tends to be short-lived. Reviews of the evidence consistently describe steroids as offering short-term relief for fatigue and appetite loss in advanced cancer, with the gains often fading after a few weeks.¹⁸ This time-limited window is why palliative care teams typically reserve steroids for specific periods when symptom burden is highest rather than prescribing them indefinitely.

Side Effects and the Cost of Prolonged Use

Steroids are never free. Even short courses carry risks, and the side-effect profile becomes more significant the longer a patient stays on them. Some adverse effects are cosmetic and demoralizing, like the rounded “moon face” that develops with prolonged use. Others are medically serious. Corticosteroids raise blood sugar, which can unmask or worsen diabetes. They suppress the immune system broadly, increasing the risk of infections, including serious ones that may go undetected because the steroids also mask the usual signs of infection like fever. Muscle weakness (steroid myopathy), bone loss, and bone death (avascular necrosis) are all recognized complications of extended use. About 5% of cancer patients on corticosteroids have them withdrawn because of unacceptable side effects.¹⁹

A frequently overlooked cost is the psychiatric one. A 10-year review of oncology patients referred for psychiatric assessment found that 11% of all referrals had a steroid-induced mental disorder. The most common symptoms were insomnia, anxiety, and irritability. Three-quarters of those patients needed psychiatric medication, most commonly antipsychotics. The encouraging finding was that the vast majority, about 90%, experienced complete or partial resolution of symptoms once the steroids were adjusted and supportive treatment was in place.²⁰ Patients and families are often caught off guard by mood changes, sleep disruption, or agitation during steroid treatment, and knowing that these effects are common, recognized, and usually reversible can make a meaningful difference in how people cope with them.

Experimental Approaches to Steroid Delivery

One area of active research aims to take advantage of what steroids do to the tumor microenvironment while minimizing their systemic side effects. Solid tumors often build up a dense, disorganized network of blood vessels and surrounding tissue that makes it hard for chemotherapy drugs to penetrate the tumor mass. Dexamethasone can “normalize” this microenvironment, making the blood vessels less chaotic and the surrounding tissue less dense, which could theoretically allow chemotherapy to reach more cancer cells.

The challenge is delivering the steroid specifically to the tumor rather than flooding the whole body. Researchers have experimented with nanoparticle delivery systems that encapsulate dexamethasone and coat it with cancer cell membranes to help it accumulate at the tumor site. In preclinical models of gynecologic cancers, this approach appeared to remodel the tumor microenvironment and improve the effectiveness of subsequent chemotherapy.²¹ This is still far from the clinic, but it reflects a growing interest in repurposing steroids not as blunt systemic tools but as targeted agents that modify the tumor’s local environment to make other treatments work better.

Why “Do Steroids Shrink Tumors” Is the Wrong Question

The most common misconception about steroids in cancer treatment is that they are prescribed to shrink tumors and that if the tumor does not shrink, the steroids have failed. In reality, tumor shrinkage is only the goal in a small subset of cases, primarily blood cancers. For the vast majority of cancer patients who receive steroids, the purpose is something else entirely: reducing dangerous swelling, preventing nausea, managing the side effects of other treatments, correcting hormonal imbalances, or improving quality of life in advanced disease. A patient with brain metastases who can walk again after starting dexamethasone has not had their tumor shrink, but the clinical benefit is just as real. A patient with advanced lung cancer who can eat a meal without vomiting after steroid-supported chemotherapy is getting a genuine therapeutic effect, even though the steroid is not touching the cancer directly. Thinking of steroids as purely tumor-shrinking drugs misses most of what they actually do in oncology, which is to make the rest of treatment possible, tolerable, and more effective.